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Abstract 
  Sensing potentially harmful bitter substances in the oral cavity is achieved by a group of ~25 
receptors, named TAS2Rs, which are expressed in specialized sensory cells and recognize individual 
but overlapping sets of bitter compounds. The receptors differ in their tuning breadths ranging from 
narrowly to broadly tuned receptors. One of the most broadly tuned human bitter taste receptors is 
the TAS2R14 recognizing an enormous variety of chemically diverse synthetic and natural bitter 
compounds, including numerous medicinal drugs. This suggests that this receptor possesses a large 
readily accessible ligand binding pocket. To allow probing the accessibility and size of the ligand 
binding pocket. Mefenamic acid (2-(2,3-dimethylphenyl)aminobenzoic acid) and diclofenac (2-(2,6-
dichloranilino) phenylacetic acid) have been identified as novel TAS2R14 agonists in a recent in 
silico screening of agonists and confirmed by functional assays, a previously identified TAS2R14 
agonist. Benzoin (2-hydroxy-1,2-di(phenyl)ethanone), which represents the most simple aromatic 
hydroxyl ketone and is a naturally in bitter almond oil, also belongs to  TAS2R14 agonists. Bad 
contacts were observed between the hydrogen of the ligand alkoxy groups and the backbone Il2627.35, 
diclofenac derivatives cannot be accommodated in the binding pocket because of seteric hindrance. 
The resulting mefenamic acid benzyl ester retained agonistic properties, although the lack of receptor 
activation below a concentration of 10 µM indicates reduced potency. for both benzoin derivatives 
receptor responses already at concentrations of 10 µM, whereas the necessary concentration of 
unmodified benzoin required to activate TAS2R14 was ~10-fold higher. Mefenamic acid and 
diclofenac show an intramolecular H-bond between the alkoxy group and the aniline nitrogen, not 
present in the benzoin structure. Different derivatives alkyl/ benzyl of diclofenac,  mefenamic acid 
and benzoin were synthesized and tested against TAS2R14. The derivatives with global minima with 
the substituent positioned far from the core of the compound skeleton structure (aniline nitrogen or 
carbonyl group), such as mefenamic acid hexyl, mefenamic acid decyl esters, benzoin benzyl and 
benzoin hexyl ethers, cause the activation of TAS2R14 to a variable extent, while the compounds 
with global minima for which substituent is placed near the structural core of the compound, such as 
in diclofenac derivatives, did not activate TAS2R14. Therefore, the difference between the 
mefenamic acid and benzoin derivatives on the one hand and the diclofenac derivatives on the other 
hand can be attributed to steric effects. 
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Chapter one 
1. Introduction 
1.1. Background: 
 
The palatability of the active ingredient of a drug is a significant obstacle in developing a 
patient friendly dosage form. Organoleptic properties, such as taste, are an important 
factor when selecting a certain drug from the generic products available in the market that 
have the same active ingredient. It is a key issue for doctors and pharmacists 
administering the drugs and particularly for the pediatric and geriatric populations. 
Nowadays, pharmaceutical companies are recognizing the importance of taste masking 
and a significant number of techniques have been developed for concealing the 
objectionable taste [1]. 
 
The word “medicine” for a child is considered a bad thing to administer because of its 
aversive taste. Medicines dissolve in saliva and bind to taste receptors on the tongue 
giving a bitter, sweet, salty, sour, or umami sensation. Sweet and sour taste receptors are 
concentrated on the tip and lateral borders of the tongue respectively. Bitter taste is 
sensed by the receptors on the posterior part of the tongue and umami taste receptors are 
located all over the tongue. A short period after birth, infants reject bitter tastes and prefer 
sweet and umami tastes [1]. Children have larger number of taste buds than adults which 
are responsible for sensitivity toward taste. These taste buds regenerate every two weeks. 
Taste becomes altered as a function of the aging process, which explains why most 
children find certain flavors to be too strong when adults do not. The American Academy 
of Pediatrics estimates that compliance in children is as low as 53%, indicating that 
children frequently fail to take medications properly. Noncompliance can lead to: (1) 
persistent symptoms, (2) need for additional doctor visits or even hospitalizations, (3) 
worsening of condition, (4) need for additional medications, (5) increased healthcare 
costs and (6) development of drug-resistant organisms in cases of infectious diseases [2].  
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In mammals, taste buds are groups of 30-100 individual elongated "neuroepithelial" cells 
which are often embedded in special structure in the surrounding epithelium known as 
papillae. Just below the taste bud apex, taste cells are joined by tight junctional 
complexes that prevent gaps between cells. Food molecules cannot therefore squeeze 
between taste cells and get into the taste bud. 
 
Taste papillae located on the tongue appear as little red dots, or raised bumps, particularly 
at the front of the tongue called "fungi form" papillae. There are three other kinds of 
papillae, foliate, circumvallates and the non-gustatory fili form. In mammals taste buds 
are located throughout the oral cavity, in the pharynx, the laryngeal epiglottis and at the 
entrance of the esophagus. Taste perception fades with age; on average, people lose half 
their taste receptors by time they turn 20 [3].The sensation of taste can be categorized 
into five basic tastes: sweetness, sourness, saltiness, bitterness, and umami. Taste buds 
are able to differentiate among different tastes through detecting interaction with different 
molecules or ions. Sweet, umami, and bitter tastes are triggered by the binding of 
molecules to G protein-coupled receptors on the cell membranes of taste buds. Saltiness 
and sourness are perceived when alkali metal or hydrogen ions enter taste buds, 
respectively [4]. As taste senses both harmful and beneficial things, all basic tastes are 
classified as either aversive or appetitive, depending upon the effect the things they sense 
have on our bodies [5]. Sweetness helps to identify energy-rich foods, while bitterness 
serves as a warning sign of poisons [6]. 
 
For a long period, it was commonly accepted that there is a finite and small number of 
"basic tastes" of which all seemingly complex tastes are ultimately composed. As of the 
early twentieth century, physiologists and psychologists believed there were four basic 
tastes: sweetness, sourness, saltiness, bitterness. At that time umami was not proposed as 
a fifth taste but now a large number of authorities recognize it as the fifth taste 
[7]. In Asian countries within the sphere of mainly Chinese and Indian cultural 
influence, pungency (piquancy or hotness) had traditionally been considered a sixth basic 
taste. Today, the consensus is that sweet ,amino acid (umami), and bitter taste converge 
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one common transduction channel, the transient receptor potential channel TRPM5, via 
phospholipase C (PLC). TRPM5 is a newly discovered TRP related to other channels in 
sensory signaling systems. It has been shown that PLC, a major signaling effect or of G-
protein coupled receptors (GPCRs), and TRPM5 are co expressed with T1Rs and T2Rs 
and are vital for sweet, amino acid, and bitter taste transduction. Activation of T1R or 
T2R receptors by their respective taste molecules would stimulate G proteins, and in turn 
PLC (PLC-ß2). The activation of PLC generates two intracellular messengers -IP3 and 
di-acyl glycerol (DAG) - from the hydrolysis of phosphatidylinositol-4,5-bisphosphate 
(PIP2)and opens the TRPM5 channel, resulting in the generation of a depolarizing 
receptor potential. Other additional pathways may modulate sweet, amino acid, or bitter 
taste reception but would not, themselves, trigger a taste response. It is not at present 
known how PLC activates TRPM5 or whether DAG is involved [8-18].                                                                                                                                                                   
1.1.1 Taste Masking 
 
There are numerous pharmaceutical and over the counter (OTC) preparations that contain 
active ingredients, which are bitter in taste. With respect to OTC preparations, such as 
cough and cold syrups, the bitterness of the preparation leads to lack of patient 
compliance. Among examples that are commonly used drugs with bitter taste; 
pseudoephedrine, a sympathomimetic drug of the phenethylamine and amphetamine. It 
may be used as a nasal/sinus decongestant, as a stimulant, or as a wakefulness-promoting 
agent [19], dextromethorphan an antitussive (cough suppressant) drug. It is one of the 
active ingredients in many over-the-counter cold and cough medicines.  
 
Dextromethorphan has also found other uses in medicine, ranging from pain 
relief to psychological applications. It is sold in syrup, tablet, spray, and lozenge forms. 
In its pure form, dextromethorphan occurs as a white powder [20], dyphylline also known 
as dipprophyllinea xanthine derivative with bronchodilator and vasodilator effects. It is 
used in the treatment of respiratory disorders like asthma, cardiac, and bronchitis. It acts 
as an adenosine receptor antagonist and phosphodiesterase inhibitor [21]. phenylephrine 
is a selective α1-adrenergic receptor agonist used primarily as a decongestant, as an agent 
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to dilate the pupil, and to increase blood pressure [22]. Phenylephrine is marketed as a 
substitute for the decongestant pseudoephedrine, chlorhexidine a chemical antiseptic. It is 
effective on both Gram-positive and Gram-negative bacteria, although it is less effective 
with some Gram-negative bacteria. It has both bactericidal and bacteriostatic mechanisms 
of action, the mechanism of action being membrane disruption, not ATPase inactivation 
as previously thought [23]. It is also useful against fungi and enveloped viruses, though 
this has not been extensively investigated, atorvastatin a member of the drug class known 
as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents 
strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin 
works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a 
key role in production of cholesterol in the body [22], loperamide 
a piperidine derivative, is an opioid drug used against diarrhea resulting from 
gastroenteritis or inflammatory bowel disease. In most countries it is available generically 
[24]. terfenadine was an antihistamine formerly used for the treatment 
of allergic conditions. It was brought to market by Hoechst Marion Roussel (now Sanofi-
Aventis) and marketed under various brand names. According to its manufacturer, 
terfenadine had been used by over 100 million patients worldwide as of 1990 [25]. It was 
superseded by fexofenadine in the 1990s due to the risk of a particular type of disruption 
of the electrical rhythms of the heart (specifically cardiac arrhythmia caused by QT 
interval prolongation) [22], prednisolone is a synthetic glucocorticoid, a derivative 
of cortisol, which is used to treat a variety of inflammatory and auto-immune conditions. 
It is the active metabolite of the drug prednisone and is used especially in patients 
with hepatic failure, as these individuals are unable to metabolize prednisone into 
prednisolone [22], salbutamol, or albuterol (USAN) is a short-acting β2-adrenergic 
receptor agonist used for the relief of bronchospasm in conditions such as 
asthma and chronic obstructive pulmonary disease. It is marketed as Ventolin among 
other brand names. Salbutamol was the first selective β2-receptor agonist to be marketed 
– in 1968. It was first sold by Allen & Hanburys under the brand name Ventolin. The 
drug was an instant success, and has been used for the treatment of asthma ever since 
[26]. guaifenisen, or guaiphenesin (former BAN), also glyceryl guaiacolate, is 
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an expectorant drug sold over the counter and usually taken orally to assist the bringing 
up (expectoration) of phlegm from the airways in acute respiratory tract infections [22] 
and amoxicillin a moderate-spectrum, bacteriolytic, β-lactam antibiotic used to treat 
bacterial infections caused by susceptible microorganisms. It is usually the drug of choice 
within the class because it is better absorbed, following oral administration, than other β-
lactam antibiotics. Amoxicillin is one of the most common antibiotics prescribed for 
children. The drug became available in 1972 [22]. 
 
1.1.2 Challenges and criteria for pursuing masking bitter taste approaches  
 
The most significant challenges that facing developers when pursuing masking bitter 
taste drugs approaches are: (i) Safety, tolerability and efficacy of the compound which 
are based on non-clinical testing, and physicochemical properties such as solubility, 
permeability and stability, (ii) lack of robust and reliable techniques for early taste 
screening of compounds with limited toxicity data, (iii) structure–taste relationships of 
pharmaceutically active molecules is limited, (iv) The perception of taste of 
pharmaceuticals has been shown to be different between adults and children and it might 
differ between healthy and patient children [4] and (v) ethical concerns to perform taste 
studies in healthy children unless the study is a „swill and spit‟ one with drugs known to 
have a good safety profile [27-29]. 
1.2 Bitter taste masking approaches (techniques) 
 
A variety of taste masking approaches has been used to address the patient compliance 
problem. With strongly bad tasting medications even a little exposure is sufficient to 
perceive the bad taste. Conventional taste masking methods such as the use of 
sweeteners, amino acids and flavoring agents alone are often inadequate in masking the 
taste of highly bitter drugs. Drugs such as macrolide antibiotics, non-steroidal anti-
inflammatory such as ibuprofen, quinine, celecoxib, etoricoxib, levofloxacin and 
penicillins have a pronounced bitter taste [30]. Masking the taste of water soluble bitter 
drugs, especially those given in high doses, is difficult to achieve by using sweeteners 
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alone. As a consequence, several approaches have been investigated and have resulted in 
the development of more efficient techniques for masking the bitter taste of active 
ingredients. All of the developed techniques are based on the physical modification of the 
formulation containing the bitter tastant. Among the approaches used to mask bitter taste 
of pharmaceuticals are: (1) taste masking using flavors, sweeteners, and amino acids. 
This technique is the foremost and the simplest approach for taste masking, especially in 
the case of pediatric formulations, chewable tablets, and liquid formulations. However, it 
is not an ideal to be used for highly bitter and highly water soluble drugs. An example for 
such approach is the use of monosodium glycyrrhizinate together with flavors to mask 
the bitter taste of guaiphenesin (an expectorant drug). Taste masked  
   
lamivudine (antiretroviral drug) was prepared by using lemon, orange and coffee flavors 
[3,31]; (2) taste masking with lipophilic vehicles such as: i) Lipids; acetaminophen 
granules are sprayed with molten stearyl stearate, mixed with suitable tablet excipients, 
and incorporated into a taste masked, chewable tablet formulation and (ii) lecithin and 
Lecithin-like substances; formulations with lecithin or lecithin-like substances in large 
quantities are believed to efficiently mask bitter taste of pharmaceuticals [3]. An example 
of a drug formulation containing lecithin-like substance is the one composed of 
magnesium aluminum silicate with soybean lecithin and talampicillin HCl (antibiotic 
drug); (3) coating is one of the most efficient and commonly used taste masking 
techniques. It is more efficient technology for aggressively bitter drugs even though 
coating imperfections, if present, reduce the efficiency of the technique. Coating of 
tablets, pellets or any other kind of particles with a film-forming polymer is a successful 
approach to provide a physical barrier, concealing unpleasant odors and bitter taste. 
Additionally, it can prevent penetration of moisture into the formulation. Coating 
materials can be selected from a wide range of hydrophobic and hydrophilic polymers 
such as polyvinylpyrrolidone, polyvinyl alcohol and cellulose derivatives. The ideal 
polymer for taste-masking, odor suppression and moisture protection should prevent 
dissolution of the dosage form in the mouth, but should be readily soluble in the stomach. 
Coating is classified based on the type of coating material, coating solvent system, and 
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the number of coating layers. Taste masked famotidine (a drug for ulcer treatment) 
formulated by using a combination of water soluble polymers like polyvinylpyrrolidone 
and insoluble polymers like cellulose acetate  is an example of such technique. Other 
various inert coating agents can be used to coat bitter drugs. These coating agents simply 
provide a physical barrier over the drug particles. Examples for such coating agents are 
starch, povidone, gelatin, methylcellulose, ethyl cellulose and etc. One of the most 
efficient Method of drug particle coating is the fluidized bed processor [4]. In this 
approach, powders as fine as 50 um are fluidized in an expansion chamber by means of 
heated, high-velocity air, and the drug particles are coated with a coating solution 
introduced usually from the top as a spray through a nozzle. Increasing the length of the 
coating cycle can increase coating thickness. Taste masking of Ibuprofen has been 
successfully achieved by this technique [4]; (4) microencapsulation is a technique 
applicable to protect materials from oxidation, volatilizing as well as to mask their bitter 
tastes [6]. Microencapsulation processes are commonly based on the principle of solvent 
extraction or evaporation. Microencapsulation as a process has been defined by Bakan [6] 
as a means of applying relatively thin coating to small particles of solid, droplets of liquid 
and dispersion. This process can be used for masking the bitter taste of drugs by 
microencapsulating drug particles with various coating agents. Coating agents employed 
includes gelatin, povidone, HPMC, ethyl cellulose, Bees wax, carnauba wax, acrylics and 
shellac. Bitter-tasting drugs can be first encapsulated to produce free flowing 
microcapsules, which are then blended with other excipients and compressed into tablets. 
Microencapsulation also increases the stability of the drug. It can be accomplished by a 
variety of methods, including air suspension, coacervation-phase separation, spray drying 
and congealing, pan coating, solvent evaporation and multi-orifice centrifugation 
techniques; (5) taste suppressants and potentiators  such as the Linguagen‟s bitter 
blockers (e.g. adenosine monophosphate) are used for masking bitter taste of various 
compounding by competing with the latter on  binding to the G-protein coupled receptor 
sites (GPCR) [32]; (6) ion exchange resins are water insoluble, cross-linked polymers 
containing salt forming groups in repeating position on the polymer chain. Drug can be 
bound to the ion exchange resin by either repeated exposure of the resin to the drug in a 
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chromatographic column or by prolonged contact of resin with the drug solution. The 
resins forms insoluble adsorbates or resinates through weak ionic bonding with 
oppositely charged drugs. The exchange of counter ions from resin is competitive. Most 
of the bitter drugs have amine as a functional group, which is the cause of their 
obnoxious taste. If the functional groups are blocked by complex formation the bitterness 
of the drug reduces drastically. A drug- resin complex is made from the bitter drugs and 
ion - exchange resins. The nature of the drug- resin complex is such that the average pH 
of 6.7 and cation concentration of about 40 meq/ lit in saliva are not able to break the 
drug- resin complex but it is weak enough to be broken down by the hydrochloric acid 
present in the stomach. Thus the drug: resin complex is absolutely tasteless and stable, 
with no after taste, but at the same time its bioavailability is not affected. Ion exchange 
resin like Amberlite was used to formulate taste masked fast dissolving orally 
consumable films of dextromethorphan (cough suppressant drug) [33,34]; (7) inclusion 
complexes in which the drug molecule fits into the cavity of a complexing agent forming 
a stable complex. The obtained complexing agent has the potential to mask the bitter taste 
of a drug by either decreasing its oral solubility on ingestion, or decreasing the amount of 
drug particles exposed to taste buds, thus reducing the perception of bitter taste. The 
inclusion complexes with cyclodextrin owe their existence to van der Waals forces 
between the host and guest. Cyclodextrin is the most widely used complexing agent for 
inclusion type complexes. It is a sweet, nontoxic, cyclic oligosaccharide derived from 
starch. Cyclodextrin forms inclusion complexes with organic molecules both in solid 
state and in solution [35]; (8) pH modifiers are capable of generating a specific pH 
microenvironment in aqueous media that has the ability to facilitate in situ precipitation 
of the bitter drug compound in saliva thus reducing the overall taste sensation for liquid 
dosage forms like suspension [36]; (9) adsorbates which are commonly used with other 
taste masking technologies to mask pharmaceuticals bitterness. The pharmaceutical may 
be adsorbed or/and entrapped in the matrix of the adsorbate porous, which may result in a 
delayed release of the bitter tastant during the passage through the oral cavity and hence 
achieving taste masking [37]; (10) chemicals; the solubility and absorption of drugs can 
be modified by the formation of molecular complexes. Lowering drug solubility through 
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molecular complexation can decrease the intensity of bitterness. Higuchi and Pitman [38] 
reported that caffeine forms complexes with organic acids that are less soluble than 
xanthenes and as such can be used to decrease the bitter taste of caffeine; (11) solid 
dispersions; solid dispersion have been defined as dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state prepared by melting (fusion) solvent 
or melting solvent method. Solid dispersion is also called as co precipitates for those 
preparation obtained by solvent method such as co precipitates of sulphathiazole and 
povidone. Solid dispersions using insoluble matrices or bland matrices may be used to 
mask the bitter taste of drugs. Also using them as absorbates on various carriers may 
increase the stability of certain drugs [39]; (12) multiple emulsions; a novel technique for 
taste masking of drugs employing multiple emulsions has been prepared by dissolving 
drug in the inner aqueous phase of w/o/w emulsion under conditions of good shelf 
stability. The formulation is designed to release the drug through the oil phase in the 
presence of gastrointestinal fluid [40]; (13) using liposomes is another way of masking 
the unpleasant taste of therapeutic agent is to entrap them into liposome.  
1.3 Human bitter taste receptors 
 
Within the oral cavity bitter substances are released from foodstuff resulting in the 
activation of one or several of the ~25 functional human bitter taste receptors of the taste 
2 receptor family (TAS2R), that belongs to the large family of G protein-coupled 
receptors (GPCRs) [43]. Previous screening efforts of heterologously expressed human 
TAS2Rs resulted in the deorphanization of 21 out of the 25 receptors [44]. The ability to 
associate the majority of TAS2Rs with activating bitter substances revealed several 
important features of the TAS2R gene family. Firstly, a single bitter compound can 
activate multiple TAS2Rs and, vice versa, TAS2Rs can respond to several bitter 
substances. Secondly, the TAS2Rs‟ agonist recognition profiles range from broadly to 
narrowly-tuned. A recent screening experiment using more than 100 natural and synthetic 
bitter compounds demonstrated that the three most broadly tuned receptors TAS2R10, 
TAS2R14, and TAS2R46 each recognized about one-third of the tested substances, and 
that their combined response profiles accounted for the detection of already one-half of 
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all substances [45]. Hence, these receptors may contribute disproportionally to human 
bitter tastant recognition. Two of these receptors, the TAS2R46 and the TAS2R10, have 
been subjected to detailed structure-function analyses to elucidate the architecture of their 
binding pockets which enable the recognition of so many structurally different bitter 
substances while maintaining a high level of selectivity. It was shown that these TAS2Rs 
possess single ligand binding pockets tailored to recognize multiple diverse bitter 
agonists [46]. Although TAS2R14 has been among the first deorphanized TAS2Rs, 
similar experiments for this receptor are lacking. In fact, the original report already 
recognized that this receptor may exhibit an exceptionally broad tuning, with no apparent 
common chemical motifs among the identified agonists. By combined in silico prediction 
of potentially agonistic molecules and subsequent functional screening of candidate 
agonists, numerous additional and previously unknown activators of TAS2R14 were 
revealed. The data suggested that, instead of a single common pharmacophore, a number 
of different chemical scaffolds may exist among TAS2R14 agonists. Moreover, it turned 
out that a considerable number of the newly identified agonists of this receptor represent 
important drugs with anti-inflammatory, analgesic, and anti-tumor activities [47]. 
Knowledge about the chemical features of agonists is of outmost importance for 
identifying potential off-target activities of medical drugs. The fact that TAS2R14 is the 
most abundant TAS2R in human heart tissue [48], underscores the importance for a 
precise knowledge on structure-activity relationships among its agonists. Moreover, an 
improved knowledge about chemical structures common to agonists may help to 
repurpose existing drugs, or rationally design novel TAS2R14 antagonists. Although at 
present only few reasonably specific TAS2R antagonists have been identified, the 
majority of these molecules share common chemical structures with the corresponding 
receptor agonists [49]. 
To elucidate the structural requirements for TAS2R14 agonists and to probe the size of 
the TAS2R14 binding pocket we performed functional calcium imaging experiments. In 
contrast to previous studies, which mostly relied on testing commercially available 
compounds, we tailored novel test compounds, based on known agonists, by chemical 
syntheses [50]. The agonist activities of the newly synthesized substances were 
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determined and directly compared with those of the corresponding mother substances. 
Density functional theory (DFT) and modeling computational methodologies were 
integrated to analyze the results. This approach allowed the investigation of binding 
pocket requirements in an extraordinary broadly tuned receptor with great precision. 
    
   Table (1): Specific area of tongue. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure (1): Locations of taste sensors on the tongue 
 
Taste is an important issue for orally administered drugs; one of the most serious 
problems for drug formulation is the undesirable drug‟s taste. Drugs bitterness might 
reduce patient compliance thus decreasing therapeutic effect especially in children 
patients. Therefore, masking the bitter taste of a drug is an important issue in the 
pharmaceuticals industry. 
Taste Area of tongue 
Sweet Tip 
 Salt Tip and Sides 
Sour Sides 
Bitter Back 
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1.4 General Objective 
 
The main goal of this thesis was to synthesize, characterize novel bitter tastants 
derivatives: diclofenac hexyl and benzyl, mefenamic hexyl, decyl and benzyl, bezoin 
hexyl and benzyl aiming to understand the nature and the mode in which bitter taste 
receptor 14 activates bitter tastants. 
 
 
 Specific objectives: 
1- To synthesize, characterize the following novel derivatives: diclofenac hexyl and 
benzyl, mefenamic hexyl, decyl and benzyl, bezoin hexyl and benzyl. 
2- To study the agonist effect of the derivative towards bitter receptor 14. 
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Chapter Two 
2. Literature Review 
 
2.1. Bitter taste masking: 
 
In 2011, Aditi Tripathi et al. declared that taste is an important parameter in case of drugs 
administering orally. Taste masking becomes a prerequisite for bitter drugs to improve 
the patient compliance especially in the pediatric and geriatric population. The problem 
of bitter taste of drug in pediatric formulations is a challenge to the formulators in the 
present scenario. Masking the bitter taste of drugs is a potential tool for the improvement 
of patient compliance which intern decides the commercial success of the product. Two 
approaches are commonly utilized to overcome the bad taste of the drug. The first 
includes reduction of drug solubility in the saliva and the second approach is to alter the 
ability of the drug to interact with taste receptor. Various methods are available to mask 
the undesirable taste of the drugs. Some of them are coating of drug particles, by 
formation of inclusion complexes, molecular complexes of drugs with other chemicals, 
solid dispersions, melting method, micro encapsulation, prodrugs, mass extrusion 
methods and ion exchange resins [51]. 
 
In 2007, Shagufta Khan et al. have studied approaches to mask the bitter taste of 
ondansetron. The purpose of their research was to mask the intensely bitter taste of 
ondansetron HCl and to formulate a rapid disintegrating tablet (RDT) of the taste-masked 
drug. Taste masking was done by complexing ondansetron HCl with aminoalkyl 
methacrylate copolymer (Eudragit EPO) in different ratios by the precipitation method. 
Drug-polymer complexes (DPCs) were tested for drug content, in vitro taste in simulated 
salivary fluid (SSF) of pH 6.2, and molecular property. Complex that did not release drug 
in SSF was considered taste-masked and selected for formulation RDTs. The complex 
with drug-polymer ratio of 8∶2 did not show drug release in SSF; therefore, it was 
selected. The properties of tablets such as tensile strength, wetting time, water absorption 
ratio, in vitro disintegration time, and disintegration in the oral cavity were investigated 
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to elucidate the wetting and disintegration characteristics of tablets. Polyplasdone XL-10 
7% wt/wt gave the minimum disintegration time. Tablets of batch F4 containing spray-
dried mannitol and microcrystalline cellulose in the ratio 1∶1 and 7% wt/wt Polyplasdone 
XL-10 showed faster disintegration, within 12.5 seconds, than the marketed tablet (112 
seconds). Good correlation between in vitro disintegration behavior and in the oral cavity 
was recognized. Taste evaluation of RDT in human volunteers revealed considerable 
taste masking with the degree of bitterness below threshold value (0.5) ultimately 
reaching to 0 within 15 minutes, whereas ondansetron HCl was rated intensely bitter with 
a score of 3 for 10 minutes. Tablets of batch F4 also revealed rapid drug release (t90, 60 
seconds) in SGF compared with marketed formulation (t90, 240 seconds; P<.01). Thus, 
results conclusively demonstrated successful masking of taste and rapid disintegration of 
the formulated tablets in the oral cavity [52]. 
2.2 Selected Drugs  
2.2.1 Mefenamic acid 
 
In 2007, Dev. et al.  have synthesized  mefenamic  acid-β-cyclodextrin  prodrug.  The 
primary hydroxy group of β- cyclodextrins was used to block the free acid group of 
mefenamic acid. The synthesis consisted of several protection and deprotection steps. 
The study demonstrated that mefenamic acid-β-cyclodextrin prodrug has retained its  
pharmacological  activity  as  was  evident  by  the  percentage  inhibition  of  edema and  
in acetic  acid  induced  writhing  method  and  comparison  with  the  activity  of  its  
active  parent drug.  In  addition,  the  study  showed  that  the  maximum  activity  of  the  
ester  prodrug  was obtained after 6  hours  indicating that there  is  no drug absorption  in 
the  stomach. Further, in vitro studies showed the ester was completely stable in 
simulated gastric and intestinal fluid whereas it underwent complete hydrolysis in rat 
fecal contents representing the colon. Ulcerogenicity  studies  showed  that  the  ester  
prodrug  is  not  ulcerogenic  indicating  that masking   the   carboxyl   group   in   
mefenamic   acid   is   a   good   approach   to reduce   the ulcerogenicity, a major side 
effect of the active parent drug, mefenamic acid [53]. 
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2.2.2 Diclofenac sodium 
 
Taste masking of diclofenac sodium using microencapsulation, were successfully 
prepared using a system of ethylcellulose (EC)-toluene-petroleum ether. The prepared 
microcapsules were taste evaluated by a taste panel of 10 volunteers. Microcapsules 
containing PEG 20% or DEP 40% showed a faster rate of DS release compared to that 
obtained from other microcapsules and crushed commercial enteric coated tablets 
(Voltaren). The palatability and the taste of DS were significantly improved by 
microencapsulation. The extent of taste masking was influenced by the microcapsule 
core: wall ratio, the presence of additives within the core, the type and concentration of 
plasticizer and initial core size [54]. 
 
Bitter taste of diclofenac sodium by  formulate an orally-disintegrating tablet (ODT) to 
achieving effective taste masking include various physical and chemical methods that 
prevent the drug substance from interaction with the taste buds. Veegum (magnesium 
aluminum silicate) as the taste masking agent and sodium starch glycolate and 
croscarmellose sodium as superdisintegrants. Granules of diclofenac sodium were 
prepared using different ratios of veegum (1:0.5, 1:1, 1:1.5, 1:2) by wet granulation 
method and evaluated for pre-compression parameters. Concluded that taste masked 
diclofenac sodium fast disintegrating tablets can be successfully prepared using veegum 
as a taste masking agent (1:1.5) and the sodium starch glycolate and croscarmellose 
sodium (5%) as superdisintegrants [55]. 
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3. Materials and Methods 
3.1.Chemical syntheses and analysis 
 
Inorganic salts were of analytical grade and were used without further purification. 
Organic buffer components were distilled or recrystallized. Distilled water was redistilled 
twice before use from all-glass apparatus. Benzoin, diclofenac sodium, mefenamic acid, 
iodohexane, iododecane, benzyl bromide, sodium hydride, sodium hydroxide, 
hydrochloric acid, sodium carbonate, anhydrous MgSO4, dioxane, dimethylformamide 
and ethyl acetate were purchased from Aldrich Chemicals Ltd and were used without 
further purification. HPLC grade solvents of methanol, acetonitrile and water were 
purchased from Sigma Aldrich. High purity dichloromethane, THF and diethyl ether (> 
99%) were purchased from Biolab (Israel). Silica gel (Silica gel 60 (0.040-0.063 mm)), 
thin layer chromatography (TLC) (TLC Silica gel 60 F254) sheets were purchased from 
Merck Ltd. The LC/ESI-MS/MS system used was Agilent 1200 series liquid 
chromatography coupled with a 6520 accurate mass quadruple-time of flight mass 
spectrometer (Q-TOF LC/MS). The analysis was performed in the positive electrospray 
ionization mode. The capillary voltage was 4.0 kV, the scanned mass range was 200-540 
m/z (MS). The high pressure liquid chromatography (HPLC) system consisted of an 
Alliance 2695 module equipped with 2996 Photodiode array detector from Waters 
(Germany). Data acquisition and control were carried out using Empower 2 ™ software 
(Waters, Germany). Analytes were separated on a 4.6 mm x150 mm XBridge® C18 
column (5 μm particle size) used in conjunction with a 4.6 x 20 mm, XBridge® C18 
guard column. Microfilters of 0.45 μm porosity were normally used (Acrodisc® GHP, 
Waters). pH meter model HM-30G: TOA electronics™ was used in this study to measure 
the pH value for the buffers. The Sep-Pack C18 6cc (1 g) cartridges were purchased form 
Waters (Milford, MA, USA). 
1
H-NMR experiments were performed with a Bruker 
AvanceII 400 spectrometer equipped with a 5 mm BBO probe. Infrared spectra (FTIR) 
for solid compounds were obtained from a KBr matrix and for liquid compounds as neat 
(4000–400 cm-1) using a PerkinElmer Precisely, Spectrum 100. 
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3.2 Synthesis of bitter taste derivatives  
 
3.2.1 Preparation of mefenamic acid, and diclofenac alkyl esters    
 
In a 250 mL round-bottom flask, diclofenac sodium or mefenamic acid (10 mmol) was 
dissolved in dry dioxane (50 mL), solutions of 2 gram sodium carbonate in dry dioxane 
(50 ml) and 40 mmol alkyl halide (1-iodohexane, 1-iododecane or benzyl bromide) in dry 
dioxane (50 ml) were added, the resulting solution was refluxed while stirring for 3 days 
(Schemes 1-3). The reaction mixture was cooled to room temperature and evaporated 
using vacuum pump to dryness. 50 ml 1N HCl and 50 ml dry ether were added to the dry 
mixture, the resulting mixture was transferred to separator funnel and shacked. The two 
layers were separated and the acidic aqueous layer was extracted twice with dry ether (50 
ml). The combined ether fractions were dried over MgSO4 anhydrous, filtered and 
evaporated to dryness using vacuum pump. The dry residue was subjected to column 
chromatography and the desired product was dried and characterized by FTIR, H-NMR 
and LC-MS analysis (see supporting information). 
 
OHO
H
N
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H
N
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Scheme 1: Synthesis of mefenamic hexyl  derivative S9 
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Scheme 2: Reaction of mefenamic acid with benzyl bromide to produce 
derivative S10: 
 
 
Scheme 3: Reaction of mefenamic acid with 1-iododecane to produce derivative. 
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Scheme 4: Synthesis of diclofenac hexyl ester derivative via reacting diclofenac sodium 
with 1-iodohexane. 
Dioxane
CH2Br
Na2CO3,
+ 
KBr
[3-(2,6-Dichloro-phenylamino)-
phenyl]-acetic acid benzyl ester
C21H17Cl2NO2
Mol. Wt.: 386.27
O
O
NH
Cl
Cl
K
O
O
NH
Cl
Cl
CH2
Scheme 5: Synthesis of diclofenac benzyl ester derivative via reacting diclofenac sodium 
with benzyl bromide. 
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3.2.2 Preparation of benzoin alkyl ethers 
 
In a 250 ml round-bottom flask, benzoin (10 mmol) was dissolved in dry dioxane (50 
mL), 60% sodium hydride (30 mmol) was added to the solution, the reaction was stirred 
at room temperature until hydrogen gas production ended, benzyl bromide or hexyl 
iodide (20 mmol) was slowly added and the reaction was mixed for overnight and then 
refluxed for two hours (Schemes 4-5). The reaction mixture was cooled to room 
temperature, few drops of 0.1 N HCl were added slowly to destroy the excess of sodium 
hydride and then the reaction mixture was evaporated to dryness. 1N NaOH (50 ml) and 
dry ether (50 ml) were added to the dry mixture; the resulting mixture was transferred to 
separator funnel and shacked. The two layers were separated and the basic aqueous layer 
was extracted twice with dry ether (50 ml). The combined ether fractions were dried over 
MgSO4 anhydrous, filtered and evaporated to dryness using vacuum pump. The dry 
residue was subjected to column chromatography and the desired product was dried and 
characterized by FTIR, H-NMR and LC-MS analysis (see supporting information). 
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Scheme 6: Reaction of benzoin with benzyl bromide to produce S12 
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Scheme 7: Reaction of  benzoin with iodohexane to produce S13 
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3.3 Functional calcium imaging experiments 
 
Functional heterologous expression of TAS2R14 was done as previously reported [6, 7, 
11]. Briefly, TAS2R14 cDNA cloned in frame with a 5‟ located sequence coding for the 
first 45 amino acids of rat somatostatin receptor 3 and a 3‟ located sequence coding for 
the herpes simplex virus glycoprotein D epitope in the vector pcDNA5FRT was 
transiently transfected into HEK 293T-Gα16gust44 cells. After a ~24 h incubation period 
cells were loaded with Fluo-4 AM in the presence of 2.5 mM probenecid, then washed 
several times with C1-buffer and placed in a fluorometric imaging plate reader. After 
application of test stimuli changes in fluorescence were monitored. As negative controls 
cells transfected with an empty expression vector were used and directly compared to 
receptor transfected cells. 
 
3.4. Computational analyses 
 
QM studies - The Becke three-parameter, hybrid functional combined with the Lee, 
Yang, and Parr correlation functional, denoted B3LYP, were employed in the 
calculations using density functional theory (DFT). All calculations were carried out 
based on the restricted Hartree-Fock method using the quantum chemical package 
Gaussian-2009 [21]. The starting geometries of all calculated molecules were obtained 
using the Argus Lab program [22] and were initially optimized at AM1, PM3, HF/6-31G 
level of theory, followed by optimization at the B3LYP/6-31G(d,p). The search for the 
global minimum structure in the mefenamic acid and diclofenac derivatives studied was 
accomplished by 36 rotations of the alkoxyl group about the C-C-Ar in increments of 
10°, and calculation of the energies of the resulting conformers. An energy minimum (a 
stable compound or a reactive intermediate) has no negative vibrational force constant. In 
case of the benzoin derivatives, 36° rotations of the alkyl group about the etheric C-O 
bond in increments of 10°, and calculation of the energies of the resulting conformers 
were conducted. 
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3.5 Homology modeling  
 
β2 adrenergic receptor (PDB ID: 3SN6) [23] was used as template for constructing 
TAS2R14 model. Sequence alignment was performed with MP-T [24] and manually 
adjusted; homology modeling was carried out with MEDELLER [25]. Hydrogen atoms 
and side chain orientations of the receptor were optimized at physiological pH with the 
Protein Preparation Wizard tool in Maestro (version 10.2, Schrödinger, LLC, New York, 
NY, 2014) and the Predict Side Chains tool in Prime (version 4.0, Schrödinger, LLC, 
New York, NY, 2014), respectively. Throughout the article, transmembrane (TM) 
residues are identified by a superscript number system according to the Ballesteros-
Weinstein numbering method [26].  
 
 
 
 
3.6 Docking  
 
Ligands were manually built using the Built facility in Maestro (version 10.2, 
Schrödinger, LLC, New York, NY, 2014). 3D structures, stereoisomers, tautomers and 
protomers at pH 7.0±0.5 were generated with LigPrep (version 4.0, Schrödinger, LLC, 
New York, NY, 2014). Glide (Grid-based Ligand Docking with Energetics) software 
(version 6.7, Schrödinger, LLC, New York, NY, 2014) was used for the Induced Fit 
Docking [27, 28]. The grid box was centroid of residues Trp 89 and Phe 247, and the van 
der Waals scalings of receptors and ligands were 0.5. Side chains of residues within 5.0 Å 
of the ligand were refined. The docking was performed with the Standard Precision (SP) 
mode of Glide. Docking poses showing similar binding modes among all compounds 
were selected and re-scored with the Extra Precision (XP) mode of Glide.  In the case of 
the diclofenac derivatives, the binding poses were obtained aligning the ligand structures 
to the diclofenac in its docking pose with Phase Shape Screening (Phase, version 4.3, 
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Schrödinger, LLC, New York, NY, 2014). Then the resulting complexes between 
TAS2R14 and diclofenac derivatives were first minimized with MacroModel (version 
10.8, Schrödinger, LLC, New York, NY, 2014) to a derivative convergence of 0.05 
kJ/mol-Å using the Polak-Ribiere Conjugate Gradient (PRCG) minimization algorithm, 
the OPLS2005 force field and the GB/SA water solvation model; and then used as input 
for Glide Pose Refinement. Glide XP was used as scoring function for all complexes (see 
Table 2). 
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Chapter Four 
4. Results and Discussion 
 
4.1 Characterization 
 
Mefenamic acid (2-(2,3-dimethylphenyl) aminobenzoic acid) and diclofenac (2-(2,6-
dichloranilino) phenylacetic acid) have been identified as novel TAS2R14 agonists in a 
recent in silico screening of agonists and confirmed by functional assays. Both substances 
represent non-steroidal anti-inflammatory drugs and are structurally similar to flufenamic 
acid, a previously identified TAS2R14 agonist which was used as a template for the in 
silico prediction of a ligand-based pharmacophore model. Benzoin (2-hydroxy-1,2-
di(phenyl)ethanone), which represents the most simple aromatic hydroxyl ketone and is a 
natural component in bitter almond oil, also belongs to the group of cognate TAS2R14 
agonists sharing the presence of two phenyl ring systems with mefenamic acid and 
diclofenac (Fig. 2) [6,11]. 
 
To analyze structural requirements of TAS2R14 agonists we first modified the most 
potent of the 3 agonists, mefenamic acid, by the addition of a third phenyl group linked to 
the carboxyl group via an ester bond (Fig. 2) and tested the compound in functional 
assays. Surprisingly, the resulting mefenamic acid benzyl ester retained agonistic 
properties, although the lack of receptor activation below a concentration of 10 µM 
indicates reduced potency (Fig. 3A). The occurrence of receptor-independent calcium 
signals already at 30 µM prevented the use of higher compound concentrations in this 
assay. The addition of an aliphatic group with an identical number of carbon atoms, 
leading to mefenamic acid hexyl ester, similarly resulted in a moderate reduction of the 
potency, yet, receptor responses were not abolished (Fig. 3A). Even the compound 
mefenamic acid decyl ester robustly activated TAS2R14-expressing cells starting from a 
concentration of ~100 µM (Fig. 3A). Thus, for a potent agonist such as mefenamic acid, 
the substantial increase of the molecular mass somewhat impairs TAS2R14 activation, 
but does not lead to a loss of activation. To determine whether chemical modification of 
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the structurally-related, but less potent agonist diclofenac shows similar tolerance, we 
tested the corresponding benzyl and hexyl esters of this compound as well. As evident 
from (Fig. 2B), diclofenac derivatives fail to activate TAS2R14 transfected cells at all 
applicable concentrations. Hence, performing the same modifications in agonists with 
lower potency resulted in pronounced changes in receptor activation. 
 
Functional heterologous expression assays do not allow assessing binding of agonist 
molecules to receptors. Instead, receptor activation is monitored. To test whether the lack 
of TAS2R14 activation by diclofenac benzyl ester has resulted from a loss of its receptor 
binding capacity or whether steric hindrance has prevented occupation of the receptor‟s 
binding pocket by the compound, we set up competition experiments using the potent 
TAS2R14 agonist aristolochic acid [6,29]. We reasoned that, if diclofenac benzyl ester 
would not fit into the receptor‟s binding pocket, aristolochic acid treatment of TAS2R14 
expressing cells should result in unimpaired receptor responses. If, however, diclofenac 
benzyl ester is able to enter the binding pocket without causing receptor activation, 
competitive inhibition of aristolochic acid activation should occur. We therefore 
challenged TAS2R14 expressing cells with increasing concentrations of diclofenac 
benzyl ester in the presence of a signal saturating concentration of aristolochic acid (3 
µM) and monitored calcium responses. The calcium traces of aristolochic acid treated 
TAS2R14 expressing cells (Fig. 3C) showed no reduction of maximal amplitudes even in 
the presence of 100 µM diclofenac benzyl ester excluding the possibility that this 
compound acts as an inhibitory ligand (antagonist) for the receptor. 
 
To confirm and extend the above observations, we modified benzoin, a TAS2R14 agonist 
with an even lower potency compared to diclofenac. Much to our surprise, the addition of 
aliphatic hexyl or aromatic benzyl side chains resulted in the generation of more potent 
agonists. For both benzoin derivatives we observed robust receptor responses already at 
concentrations of 10 µM, whereas the necessary concentration of unmodified benzoin 
required to activate TAS2R14 was ~10-fold higher (Fig. 4). Hence, despite the 
30 | P a g e  
 
pronounced chemical similarities between mefenamic acid, diclofenac and benzoin, it 
appears that their binding modes differ. 
 
To gain further insight in the binding site of TAS2R14 bitter taste receptor, we performed 
computational analyses on ligand structures, receptor structure and ligand-receptor 
interactions, aiming to identify the chemical structural factors associated with TAS2R14 
activation. Ground state structures (global minimum) for mefenamic acid, diclofenac, 
benzoin and their derivatives were calculated using QM approaches. Mefenamic acid and 
diclofenac show an intramolecular H-bond between the alkoxy group and the aniline 
nitrogen, not present in the benzoin structure. For mefenamic acid and diclofenac 
derivatives, two types of conformations were considered: one in which the alkoxy group 
is pointing towards the aniline nitrogen and another in which it is pointing far from it. It 
was found that the global minimum structures for the mefenamic acid derivatives all 
reside in a conformation where the alkoxyl group is pointing far from the aniline 
nitrogen, except for mefenamic acid benzyl ester (Fig. 3A), whereas the global minimum 
structures for the diclofenac derivatives resided in a conformation where the alkoxyl 
group is pointing towards the aniline nitrogen (Fig. 3B). Similarly, for the benzoin 
derivatives two types of conformations were considered: one in which the alkyl group is 
pointing towards the carbonyl group and another in which it is pointing far from it. It was 
found that the global minimum structures for all benzoin derivatives reside in a 
conformation where the alkyl group is pointing far from the carbonyl group (Fig. 4). The 
compounds with global minima with the substituent positioned far from the core of the 
compound skeleton structure (aniline nitrogen or carbonyl group), such as mefenamic 
acid hexyl, mefenamic acid decyl esters, benzoin benzyl and benzoin hexyl ethers, cause 
the activation of TAS2R14 to a variable extent, while the compounds with global minima 
for which substituent is placed near the structural core of the compound, such as in 
diclofenac benzyl and diclofenac hexyl esters, did not activate TAS2R14. Therefore, the 
difference between the mefenamic acid and benzoin derivatives on the one hand and the 
diclofenac derivatives on the other hand can be attributed to steric effects: the three 
dimensions of the ligands (dimensions A, B, and C, see Figs. 3 and 4) were calculated for 
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the different derivatives and demonstrate that the dimension B for diclofenac benzyl and 
diclofenac hexyl esters (11.85 Å and 11.69 Å, respectively) are much higher than that of 
all other derivatives (6.23-6.95 Å). It is worth noting that although the benzyl group in 
mefenamic acid benzyl ester is placed not far from the structure‟s core (aniline nitrogen) 
of the ester, it resides in a compact conformation (for DFT calculated global minimum 
structures for the tested compounds, see supplemental file 1). 
 
To evaluate the ability of the compounds to interact with the receptor‟s binding pocket, 
compounds were docked into a TAS2R14 homology model based on the β2 adrenergic 
receptor (PDB ID: 3SN6) [23] (Fig. 5). Mefenamic acid establishes π-π interactions with 
His94
3.37
, Phe186
5.46
 and Phe243
6.51
, and H-bonds with Asn93
3.36
 and Gln266
7.39
 side 
chains of TAS2R14 (Fig. 6A). Mefenamic acid derivatives interact with the receptor with 
a similar binding mode, but to accommodate the ester moiety; they are shifted compared 
to the original molecule (Fig. 6D and G): because of the ester substitution, interaction 
with Gln266
7.39
 is not possible and, because of the increased size, ligands cannot engage 
in all stacking interactions observed for mefenamic acid. Interestingly, in case of the 
mefenamic acid benzyl ester, the additional aromatic ring can re-establish one of these 
interactions, with improved activity compared to the other derivatives. 
 
Diclofenac has a methyl spacer between the carboxyl group and the aromatic ring, and 
has chloride atoms in ortho positions of the phenyl group (Fig. 2). These structural 
modifications affect the binding mode: the carboxyl can interact with Asn93
3.36
 but not 
with Gln266
7.39
; His94
3.37
, establishes both hydrophobic and polar interactions with the 
ligand, but there is no interaction with Phe186
5.46
 (Fig. 6B). Since the methyl spacer is 
causing a shift in diclofenac binding, the addition of the ester moiety could increase steric 
hindrance, negatively affecting binding. Docking results of diclofenac derivatives did not 
furnish any poses comparable to the diclofenac pose described above. Diclofenac 
derivatives were also aligned to diclofenac in its docking conformation, and then 
minimized to adjust the position of the alkoxy group. Both the hexyl and the benzyl esters 
have clashes with the backbone of TM7. In particular, bad contacts were observed 
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between the hydrogen of the ligand alkoxy groups and the backbone Ile262
7.35
 (shown as 
red arrows in the 2D representation of binding modes in (Fig. 5E and H). This is despite 
diclofenac derivatives being closer to TM3 than other compounds (see the 3D 
representation of binding modes in (Fig. 5E and H). Thus, diclofenac derivatives cannot 
be accommodated in the binding pocket because of steric hindrance. 
 
Benzoin and its derivatives were synthesized and tested in racemic mixture. The docking 
results of the R stereoisomers (R)‐benzoin, (R)-benzoin benzyl ester and (R)-benzoin 
hexyl ester, showed better performance and are reported here. (R)-benzoin establishes an 
H-bond with Asn93
3.36
 and aromatic interactions with Trp89
3.32
 and Phe247
6.55
 (Fig. 5C). 
Interestingly, the benzoin derivatives can interact also with His94
3.37 
(Fig. 6F and I). In 
addition, the Mulliken atomic charges for benzoin, benzoin benzyl ether and benzoin 
hexyl ether, calculated by both DFT and AM1 methods, demonstrate that the net negative 
charge value around the two oxygen atoms in both ethers is higher than in benzoin, 
enabling these oxygens to participate in stronger interactions than in benzoin. This is in 
agreement with the functional data showing that ether derivatives being more potent 
agonists than benzoin. 
4.2. Discussion 
 
The TAS2R14 is a highly promiscuous human bitter taste receptor [6,10]. The wide 
tuning breadth of the receptor may be achieved by architecture of the ligand binding 
pocket that provides a diverse array of contact points for ligand interactions as well as 
sufficient space to accommodate the various agonists. Moreover, as we have shown for 
the broadly tuned human bitter taste receptor TAS2R10, the ability to interact with many 
structurally diverse bitter substances may come with the trade-off of rather low-affinity 
binding between receptor and agonist [9]. In order to characterize the binding pocket of 
TAS2R14 in more detail, we chemically synthesized derivatives of known TAS2R14 
agonists and determined their ability to activate cells heterologously expressing the 
receptor. This approach demonstrated that TAS2R14 tolerated the additions of large 
chemical groups to the chemical backbone of ligand molecules or, in case of the benzoin 
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derivatives, even showed improved activation. This suggests that the TAS2R14 binding 
pocket is wide with few size constraints for agonists. Moreover, ligands are not only 
required to establish contacts within the receptor binding pockets, they first need to gain 
access through extracellular loops which are decorated with at least one, and in case of 
TAS2R14, with two, asparagine-linked, oligosaccharide side-chains [30]. Sequence 
deviation from crystallized GPCRs prevents reliable inclusion of loops in homology 
models and hence, understanding of the constraints for entering the binding pocket. 
Nevertheless, previous observations [8, 31] indicate that receptor residues located in 
extracellular loop areas or close to them contribute to receptor selectivity. Moreover, 
recent molecular dynamics simulations of agonist binding to human TAS2R46 suggested 
the presence of a transient, vestibular ligand binding site that may contribute to ligand 
selectivity in addition to the orthosteric binding site [32]. For the TAS2R14, steric 
exclusion of agonists seems to represent a minor constraint, because additions of large 
side-chains, as long as one ligand dimension (dimension B, cf. Figs. 4 and 5) stays below 
~7 Å, retained agonistic activity or even became more potent.  
 
Furthermore, structural analysis suggests that improved activity of benzoin derivatives 
compared to benzoin relates to hydrophobic interactions in general, and π-π stacking with 
His94
3.37
 in particular. Since mefenamic acid benzyl ester exhibited a somewhat reduced 
potency compared to mefenamic acid, the interaction with Gln266
7.39
 is of importance. 
In summary, the current work demonstrated that chemical modification of TAS2R14 
agonists allows to probe the spatial capacity of the binding pocket: the receptor TAS2R14 
is able to accommodate agonists with a wide range of sizes, as typical for multi-specific 
GPCRs [33], indicating that agonist-receptor contact points do not envelop the ligand 
tightly. This is in agreement with the finding that TAS2R promiscuity correlates with the 
binding site surface [34]. Future work elucidating the contact points between TAS2R14 
binding site residues and its agonists is necessary to reveal the molecular basis for the 
promiscuity of this receptor aside from its apparent spacious ligand binding site. 
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Figure (2): Chemical structures of the cognate TAS2R14 agonists and schematic 
representation of syntheses performed for chemical modifications. The chemical 
structures of the two anti-inflammatory drugs, mefenamic acid and diclofenac, and of the 
natural bitter substance benzoin are depicted. The synthesis strategies for mefenamic acid 
and diclofenac alkyl esters, mefenamic acid hexyl, mefenamic acid decyl, mefenamic 
acid benzyl, diclofenac hexyl and diclofenac benzyl esters as well as benzoin alkyl ethers, 
benzoin hexyl and benzoin benzyl ethers, respectively, are indicated. R-X= Hexyl iodide, 
decyl iodide (only for mefenamic acid modification), benzyl bromide. 
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Figure (3): Chemical structures, DFT-calculated 3D-cell volumes, and receptor activating 
properties of mefenamic acid and diclofenac derivatives. Chemical structures of 
mefenamic acid (A) and diclofenac (B) derivatives are provided together with molecular 
formulas and the corresponding molecular weights. Side chains added to the original 
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agonists are highlighted in red. DFT optimized structures are shown in balls and sticks 
models, the calculated surface areas are illustrated, and the dimensions in Å are given. 
Changes in fluorescence after agonist application and applied agonist concentrations are 
shown on the right. Black traces were obtained from HEK 293T-Gα16gust44 cells 
transiently transfected with TAS2R14 cDNA, gray traces represent negative controls 
obtained by stimulation of cells transfected with empty expression vector. C) To 
investigate competition for the ligand binding site of TAS2R14 different mixtures of 
aristolochic acid and diclofenac benzyl ester were added to HEK 293T-Gα16gust44 cells 
transiently transfected with TAS2R14 cDNA and fluorescence changes were monitored. 
Note the stable amplitudes obtained for the agonist aristolochic acid alone and together 
with increasing concentrations of diclofenac benzyl ester. Black traces were obtained 
from HEK 293T-Gα16gust44 cells transiently transfected with TAS2R14 cDNA, gray 
traces represent negative controls obtained by stimulation of cells transfected with empty 
expression vector. 
 
 
Figure (4): Chemical structures, DFT-calculated 3D-cell volumes, and receptor activating 
properties of benzoin derivatives. Chemical structures of the specified compounds are 
provided together with molecular formulas and the corresponding molecular weights. 
Side chains added to the original agonists are highlighted in red. DFT optimized 
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structures are shown in balls and sticks models, the calculated surface areas are 
illustrated, and the dimensions in Å are given. Changes in fluorescence after agonist 
application and the applied agonist concentrations are shown on the right. Black traces 
were obtained from HEK 293T-Gα16gust44 cells transiently transfected with TAS2R14 
cDNA, gray traces represent negative controls obtained by stimulation of cells transfected 
with empty expression vector. Note, that the addition of hydrophobic side chains to 
benzoin results in elevated potencies of the modified derivatives. 
 
 
Figure (5): Sequence alignment of modeled TAS2R14 receptor and the template X-ray 
structure of β2 adrenergic receptor (PDB ID: 3SN6). Identical residues are shown in red 
and similar residues in blue. Positions X.50 according to the Ballesteros-Weinstein 
numbering system are shaded yellow. 
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Figure (6): 3D and 2D representation of the docking pose of mefenamic acid (A), 
diclofenac (B), benzoin (C) and their derivatives (benzyl derivatives in D, E and F; hexyl 
derivatives in G, H and I) with TAS2R14 receptor. Mefenamic acid and its derivatives 
are shown in violet sticks (with the exception of mefenamic decyl ester represented in red 
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line, panel G), diclofenac and its derivatives in orange, benzoin and their derivatives in 
green. H-bond interactions are shown in magenta, π-π interactions in green and bad 
contacts are indicated by red arrows. In the 3D representations, only polar interactions are 
reported, and the distance between the ligands and C-α of the residues Ile1795.39 and 
Ile262
7.35
 are reported in dashed gray lines. In 2D representations, polar and hydrophobic 
residues are shown as cyan and green spheres, respectively. 
The mefenamic acid (S8) standard shows in the graph bitterness at 1,3,10 micro molar, 
but we observed by combining iodohexane to mefenamic (S9) less bitterness more than 
10 fold  than bezyl mefenamate (S10) were observed (Fig. 7) 
For benzoin (S11) the bitterness can be observed at 100, 300 micro molar, the bitterness 
became more agonist for benzyl benoinat (S12) and so hexyl benoinat (S13) (Fig.8) 
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Figure (7). The mefenamic acid (S8) standard shows in the graph bitterness at 
1,3,10 micro molar, but we observed by combining iodohexane to mefenamic 
(S9) less bitterness than bezyl mefenamate (S10) were observed. 
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Figure (8). For benzoin (S11) the bitterness can be observed at 100, 300 micro 
molar, the bitterness became more agonist for benzyl benoinat (S12) and so hexyl 
benzoinat (S13) 
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4.2.2 Analytical data for the synthesized organic compounds 
4.2.2.1 Mefenamic Acid- 
 
Appearance (Fig. 13): yellowish crystals M.P. 230-231 ˚C. 1H-NMR δ (ppm) CD 3 OD 
:2.16 (s, 3H, Ar-(CH3)) , 2.35 (s , 3H, Ar-(CH3) , 6.63 (t, 1H, Ar-H), 7.01(d, 2H, J=6.7 
,Ar-H), 7.11 (t, 1H, Ar-H), 7.23 (t, 1H, Ar-H), 7.94 (d, 2H,  J=1.65, Ar-H). 
 
 
 
Figure(9)
    1
H-NMR spectrum of mefenamic acid in CD3OD S8 
 
Figure (10): IR result of mefenamic acid 
43 | P a g e  
 
4.2.2.2 Mefenamic hexyl ester –  
Appearance (Fig. 10): yellowish oil. 
1
H-NMR δ (ppm) CDCl3- 0.87 (t, 3H, J=6.8 Hz, 
CH2CH3), 1.35-1.47 (m, 6H, CH2CH2CH2CH3), 1.62 (m, 2H, OCH2CH2CH2), 2.18 (s, 
3H, Ar-CH3), 2.32 (s, 3H, Ar-CH3), 4.30 (t, 2H, J =7.6 Hz, OCH2), 6.65 (d, 1H, J= 8 Hz, 
Ar-H), 7.01 (m, 2H, Ar-H), 7.10 (m, 2H, Ar-H), 7.24 (dt, 1H, J=14 Hz , Ar-H), 7.95 (dd , 
1H, J=8 Hz, Ar-H). IR (KBr/νmax cm
–1
) 3318 (NH), 2910 (alkyl), 1685 (C=O), 1607 
(C=C), 1249 (C-O), 1160 (C-O) 1085 (C-O).  m/z 326.2853 (M+1)
+
. 
 
Figure (11)  
1
H-NMR spectrum of  mefenamic hexyl in CD3OD S9 
 
Figure (12)  IR spectrum of  mefenamic hexyl  S9 
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4.2.2.3 Mefenamic benzyl ester  
Appearance (Fig. 9): yellowish crystals M.P. 107-110 ˚C. 1H-NMR δ (ppm) CDCl3- 2.18 
(s, 3H, Ar-CH3), 2.32(s, 3H, Ar-CH3), 4.91 (s, 2H, OCH2), 6.68 (m, 2H, Ar-H), 6.90 (m, 
2H, Ar-H), 7.06 (m, 1H, Ar-H), 7.22 (m, 1H, Ar-H), 7.31 (m, 1H, Ar-H), 7.45 (m, 6H, 
Ar-H), 7.97 (dd , 1H, J=8 Hz, Ar-H). IR (KBr/νmax cm
–1
) 3318 (NH), 2910 (alkyl), 1726 
(C=O), 1607 (C=C), 1249 (C-O), 1160 (C-O) 1085 (C-O).  m/z 332.2653 (M+1)
+
. 
 
Figure (13) 
1
H-NMR spectrum of mefenamic benzyl in CD3OD S10 
 
Figure (14) IR spectrum of mefenamic benzyl S10 
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4.2.2.4 Mefenamic decyl ester –  
Appearance (FNS): yellowish oil. 
1
H-NMR δ (ppm) CDCl3- 0.87 (t, 3H, J=6.8 Hz, 
CH2CH3), 1.34-1.57 (m, 14H, (CH2)7CH3), 1.51 (m, 2H, OCH2CH2CH2), 2.20 (s, 3H, 
Ar-CH3), 2.28 (s, 3H, Ar-CH3), 4.33 (t, 2H, J =7.6 Hz, OCH2), 6.67 (d, 1H, J= 8 Hz, Ar-
H), 7.04 (m, 2H, Ar-H), 7.12 (m, 2H, Ar-H), 7.24 (dt, 1H, J=14 Hz , Ar-H), 7.98 (dd , 
1H, J=8 Hz, Ar-H). IR (KBr/νmax cm
–1
) 3325 (NH), 2925 (alkyl), 1682 (C=O), 1597 
(C=C), 1259 (C-O), 1163 (C-O) 1075 (C-O).  m/z 382.2723 (M+1)
+
. 
 
Figure (15) IR spectrum of mefenamic decyl 
4.2.2.5 Diclofenac (from Ala Thesis NMR & et..) 
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Figure (16) IR spectrum of Diclofenac 
4.2.2.6 Diclofenac hexyl ester –  
Appearance (FNS): Brownish oil. 
1
H-NMR δ (ppm) CDCl3- 0.86 (t, 3H, J=6.8 Hz, 
CH2CH3), 1.24-1.30 (m, 6H, CH2CH2CH2CH3), 1.63(m, 2H, OCH2CH2CH2), 3.86 (s, 
2H, COCH2), 4.12 (t, 2H, J =7.6 Hz, OCH2), 6.53 (d, 1H, J= 8 Hz, Ar-H), 6.93 (d, 1H, J= 
21.6 Hz, CH2-Ar-H), 6.95 (t, 1H, Ar-H), 7.14 (t, 1H, Ar-H), 7.24 (d, 1H, J=1.6 Hz , Ar-
H), 7.32 (m , 2H, Ar-H). IR (KBr/νmax cm
–1
) 3361 (NH), 2955 (alkyl), 1714 (C=O), 1590 
(C=C), 1283 (C-O), 1117 (C-O), 1081 (C-O).  m/z 381.1183 (M+1)
+
. 
 
Figure (17) IR spectrum of Diclofenac hexyl ester 
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4.2.2.7 Diclofenac benzyl ester –  
Appearance (FNS): white crystals, M.P. ˃ 300 ˚C (not corrected). 1H-NMR δ (ppm) 
CDCl3- 3.86 (s, 2H, COCH2) , 5.12 (s, 2H, CH2-Ar) , 6.54 (d, 1H, J= 8 Hz, Ar-H), 6.88 
(d, 2H, J= 21.6 Hz, CH2-Ar-H), 6.97 (t, 1H, Ar-H), 7.14 (t, 1H, Ar-H), 7.24 (d, 1H, J=1.6 
Hz , Ar-H), 7.31 (d, 1H, J= 3.2 Hz, Ar-H), 7.33 (t, 5H, Ar-H). IR (KBr/νmax cm
–1
) 3361 
(NH), 1743 (C=O), 1588 (C=C), 1576 (C=C), 1563 (C=C), 1557 (C=C), 1283 (C-O), 
1178 (C-O), 1091 (C-O). m/z 387.0710 (M+1)
+
. 
 
Figure (18) IR spectrum of Diclofenac benzyl ester 
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4.2.2.8 benzoin ( 
 
Figure (19) IR spectrum of benzoin 
 
4.2.2.9 Benzoin hexyl ether –  
Appearance (Fig. 12): yellowish crystals M.P. 80-82 ˚C (not corrected). 1H-NMR δ 
(ppm) CDCl3- 0.88 (t, 3H, J=6.8 Hz, CH2CH3), 1.21-1.51 (m, 6H, CH2CH2CH2CH3), 
1.62 (m, 2H, OCH2CH2CH2), 3.88 (t, 2H, J =7.6 Hz, OCH2), 6.63 (d, 1H, J= 8 Hz, Ar-
H), 7.33 (m, 3H, Ar-H), 7.61 (m, 4H, Ar-H), 8.05 (dd , 2H, J=8 Hz, Ar-H). IR (KBr/νmax 
cm
–1
) 3318 (NH), 2910 (alkyl), 1685 (C=O), 1607 (C=C), 1249 (C-O), 1160 (C-O) 1085 
(C-O).  297.1809  (M+1)
+
. 
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Figure (20)  
1
H-NMR spectrum of benzoin hexyl in CDCl3 
 
Figure (21) IR spectrum of benzoin hexyl 
 
4.2.2.10 Benzoin benzyl ether –  
Appearance (Fig. 11): yellowish crystals M.P. 110-112 ˚C (not corrected). 1H-NMR δ 
(ppm) CDCl3- 4.41 (s, 2H, O-CH2Ph), 6.61(s, 1H, CHO-CH2Ph), 7.32 (m, 5H, Ar-H), 
7.36 (m, 2H, Ar-H), 7.38 (m, 3H, Ar-H), 7.64 (m, 3H, Ar-H), 7.94 (dd , 2H, J=8 Hz, Ar-
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H). IR (KBr/νmax cm
–1
) 1686 (C=O), 1607 (C=C), 1249 (C-O), 1160 (C-O) 1085 (C-O).  
m/z 303.1380  (M+1)
+
. 
 
 
Figure (20)  
1
H-NMR spectrum of benzoin benzyl in CDCl3 
 
Figure (22) IR spectrum of benzoin benzyl 
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Table 2: Glide XP scores for mefenamic acid, diclofenac, benzoin and their derivatives 
in complex with TAS2R14 structure. 
Ligand 
Glide XP Score 
(kcal/mol) 
Mefenamic acid 
Mefenamic benzyl ester 
Mefenamic hexyl ester 
Mefenamic decyl ester 
-12.6 
-10.5 
-9.0 
-10.0 
Diclofenac 
Diclofenac benzyl ester 
Diclofenac hexyl ester 
-9.9 
-5.2 
-5.9 
Benzoin 
Benzoin benzyl ether 
Benzoin hexyl ether 
-9.8 
-11.6 
-9.9 
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Summary: 
In summary, the current work demonstrated that chemical modification of TAS2R14 
agonists allows to probe the spatial capacity of the binding pocket: the receptor TAS2R14 
is able to accommodate agonists with a wide range of sizes, as typical for multispecific 
GPCRs, indicating that agonist-receptor contact points do not envelop the ligand tightly. 
This is in agreement with the finding that TAS2R promiscuity correlates with the binding 
site surface. Future work elucidating the contact points between TAS2R14 binding site 
residues and its agonists is necessary to reveal the molecular basis for the promiscuity of 
this receptor aside from its apparent spacious ligand binding site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 | P a g e  
 
References: 
1. Sohi H, Sultana Y, Khar RK. Taste Masking Technologies in oral 
pharmaceuticals, recent development and approaches. Drug Develop. Ind. Pharm. 
2004;30(5): 429-448. 
2. Reilly WJ. Pharmaceutical necessities in Remington: The science and practice of 
pharmacy, Mack Publishing Company; 2002. p 1018-1020. 
3. Gowan Jr. WG, Richard DB. Aliphatic esters as a solventless coating for 
pharmaceuticals. No. CA2082137. 19 Aug. 2003. 
4. Gowthamarajan K, Kulkarni G T, Kumar MN. Pop the pills without 
bitterness. Resonance 2004;9(12): 25-32. 
5. Davis JD. Drug Cosmet. India: Encyclopedia of pharmaceutical technology. 
2000;2: 1-5. 
6. Bakan JA. Microencapsulation, Theory and practice of Industrial Pharmacy, Third 
Edition 1986. p 412-429. 
7. Ikeda K. New seasonings. Chemical senses 2002;27(9): 847-849. 
8. Maehashi K, Matano M, Wang H, Vo LA, Yamamoto Y, Huang L. Bitter 
peptides activate hTAS2Rs, the human bitter receptors. Biochemical and 
biophysical research communications 2008;365(4): 851-855. 
9. Lindemann B. Receptors and transduction in taste. Nature 2001;413(6852): 219-
225. 
10. Behrens M, Meyerhof W. Bitter taste receptors and human bitter taste perception. 
Cell Mol. Life Sci. 2006;63: 1501–1509. 
11. Meyerhof  W, Born S, Brockhoff A, Behrens M. Molecular biology of 
mammalian bitter taste receptors. A review. Flavour Frag. J. 2011;26: 260–268. 
54 | P a g e  
 
12. Behrens M, Meyerhof W. Mammalian bitter taste perception. Results Probl. Cell. 
Differ. 2009;47: 203–220. 
13. Brockhoff A, Behrens M, Massarotti A, Appendino G, Meyerhof W. Broad tuning 
of the human bitter taste receptor hTAS2R46 to various sesquiterpene lactones, 
clerodane and labdane diterpenoids, strychnine, and denatonium. J. Agric. Food 
Chem. 2007;55: 6236–6243. 
14. Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, Appendino 
G, Behrens M. The molecular receptive ranges of human TAS2R bitter taste 
receptors. Chem. Senses 2010;35: 157–170. 
15. Wiener A, Shudler M, Levit A, Niv MY. Bitter DB: a database of bitter 
compounds. Nucleic acids research 2012;40(D1): D413-D419. 
16. Bufe B, Hofmann T, Krautwurst D, Raguse JD, Meyerhof W. The human 
TAS2R16 receptor mediates bitter taste in response to beta-glucopyranosides. 
Nat. Genet. 2002;32: 397–401. 
17. Sainz E, Cavenagh MM, Gutierrez J, Battey JF, Northup JK, Sullivan SL. 
Functional characterization of human bitter taste receptors. Biochem. J. 2007;403: 
537–543. 
18. Sakurai T, Misaka T, Ishiguro M, Masuda K, Sugawara T, Ito K, Kobayashi T, 
Matsuo S, Ishimaru Y, Asakura T. et al. Characterization of the beta-D-
glucopyranoside binding site of the human bitter taste receptor hTAS2R16. J. 
Biol. Chem. 2010; 285: 28373–28378. 
19. Hunter G, Wayne ED, Timothy DN, Peter S, Alicia E, Gary G. Pseudoephedrine 
is without ergogenic effects during prolonged exercise. Journal of Applied 
Physiology 1996;81: 2611–2617. 
20. Malladi M, Jukanti R, Nair R, Wagh S, Padakanti H, Matet A. Design and 
Evaluation of Taste Masked Dextromethorphan Hydrobromide Oral 
Disintegrating Tablets. Acta Pharmacetica 2010; 60: 267–280. 
55 | P a g e  
 
21. Schwabe U, Ukena D, Lohse MJ. Xanthine derivatives as antagonists at A1 and 
A2 adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 
1985;330(3): 212–21. 
22. Mycek MJ, Harvey RA, Champe RC. Lippincott's illustrated reviews 
pharmacology. Philadelphia: Lippincott-Raven; 1997. 
23. Grover R, Frank ME. Regional Specificity of Chlorhexidine Effects on Taste 
Perception; Chem Senses 2008; 33(4): 311-318. 
24. Stokbroekx RA, Vanenberk J, Van Heertum AHMT, Van Laar GMLW, Van der 
Aa MJMC, Van Bever WFM, Janssen PAJ. Synthetic Antidiarrheal Agents. 2,2-
Diphenyl-4-(4'-aryl-4'-hydroxypiperidino)butyramides. Journal of Medicinal 
Chemistry 1973; 16(7): 782–786. 
25. Thompson D, Oster G. Use of Terfenadine and Contraindicated Drugs. Journal of 
the American Medical Association (American Medical Association) 1996; 
275 (17): 1339–1341. 
26. Rossi S. Australian Medicines Handbook. AMH.ISBN 2004; 0-9578521-4-2. 
27. Karaman R.  Computationally Designed Prodrugs for Masking the Bitter Taste of 
Drugs. Journal of Drug Designing 2012;1:e106. doi:10.4172/2169-
0138.1000e106. 
28. Karaman R. “A Solution to Aversive Tasting Drugs for Pediatric andGeriatric 
Patients” Journal of Drug Designing , Drug Des. 2013;DOI:10.4172/2169-
0138.1000e116. 
29. Karaman R. “The Future of Prodrugs designed by Computational Chemistry” 
Journal of Drug Designing, 2012; 1:e103. doi:10.4172/ddo.1000e103. 
30. Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in Pharmaceutical Taste 
Masking Technologies: A Patent Review. Recent Patents on Drug Delivery & 
Formulation 2009;3: 26-39. 
56 | P a g e  
 
31. Fawzy  AA. Pleasant Tasting Aqueous Liquid Composition of a Bitter-Tasting 
Drug, PCT Int. Appl. 1998; WO9805312, 2. 
32. Zelalem A, Puri V, Kumar L, Bansal A. Trends in Pharmaceutical Taste Masking 
Technologies: A Patent Review. Recent Patents on Drug Delivery & Formulation 
2009;3, 26-39. 
33. Jain NK. Advances in controlled and Novel Drug delivery  2001; 1stEd, 290-306. 
34. Bress WS, Kulkarni N, Ambike S, Ramsay MP. 2006; EP1674078. 
35. Mendes WR. Theory and practice of Industrial pharmacy, Third Edition; 1976. 
36. Redondo AMJ, Abanades LB. 2003; WO047550. 
37. Kashid N, Chouhan P, Mukherji G. 2007; WO2007108010. 
38. Burgard A. 2003; JP026665. 
39. Lachman L, Liberman HA. Pharmaceutical Dosage Forms:Tablet”, Volume I; 
1989.p 11-14. 
40. Rao MY, Bader F. Masking the taste of chloroquine by Multiple Emulsion. The 
East. Pharm. 1993;123: 11. 
41. Kasturagi Y. Selective inhibition of bitter taste of various drugs by 
lipoprotein.Pharm. Res. 1995;12(5): 658-662. 
42. Brahmankar DM., Jaiswal SB. Biopharmaceutics & Pharmaceutics. First Edition; 
1995:pp 162-163. 
43. Rozin, P., Vollmecke, T.A. Food Likes and Dislikes. Annu Rev Nutr. 1986; 6: 
433-456. 
44. Behrens, M., Meyerhof, W. Bitter taste receptor research comes of age: from 
characterization to modulation of TAS2Rs. Semin Cell Dev Biol. 2013 ;24: 215-
221. 
57 | P a g e  
 
45. Meyerhof, W., Batram, C., Kuhn, C., Brockhoff, A., Chudoba, E., Bufe, B., 
Appendino, G., Behrens, M. The molecular receptive ranges of human TAS2R 
bitter taste receptors. Chem Senses 2010;35: 157-170. 
46. Brockhoff, A., Behrens, M., Niv, M.Y., Meyerhof, W. Structural requirements of 
bitter taste receptor activation. Proc Natl Acad Sci U S A. 2010;107: 11110-
11115. 
47. Behrens, M., Brockhoff, A., Kuhn, C., Bufe, B., Winnig, M., Meyerhof, W. The 
human taste receptor hTAS2R14 responds to a variety of different bitter 
compounds. Biochem Biophys Res Commun 2004;319: 479-485. 
48. Levit, A., Nowak, S., Peters, M., Wiener, A., Meyerhof, W., Behrens, M., Niv, 
M.Y. The bitter pill: clinical drugs that activate the human bitter taste receptor 
TAS2R14. FASEB. 2014;  J;28: 1181-1197. 
49. Foster, S.R., Blank, K., See Hoe, L.E., Behrens, M., Meyerhof, W., Peart, J.N., 
Thomas, W.G. Bitter taste receptor agonists elicit G-protein-dependent negative 
inotropy in the murine heart. FASEB. 2014;  J;28: 4497-4508. 
50. Karaman, R. Prodrugs for masking bitter taste of antibacterial drugs--a 
computational approach. J Mol Model. 2013;19: 2399-2412. 
51. Aditi Tripathi,Dipika Parmar,Dr. Upendra Patel,Ghanshyam Patel,Dhiren 
Daslaniya, Bhavin Bhiman. Taste Masking: A Novel Approach for Bitter and 
Obnoxious Drugs 2011;  JPSBR: 136-142 
52. Shagufta Khan , Prashant Kataria, Premchand Nakhat. Taste masking of 
ondansetron hydrochloride by polymer carrier system and formulation of 
rapid-disintegrating tablets 2007;pp E127-E133. 
53. Dev, S., Mhaske, D. V., Kadam, S. S., & Dhaneshwar, S. R. Synthesis and 
pharmacological evaluation of cyclodextrin conjugate prodrug of mefenamic acid. 
Indian journal of pharmaceutical sciences  2007; 69(1): 69. 
54. Al-Omarn MF., Al-Suwayeh SA., El-Helw AM. And Saleh SI. Taste masking of 
diclofenac sodium using microencapsulation 2002; 19(1); 45-52. 
58 | P a g e  
 
55. Sona. P. S., Muthalingam C. Formulation and Evaluation of Taste Masked Orally 
Disitegrating Tablets of Diclofenac Sodium. International Journal of PharmTech 
Research. 2011;Vol.3, No.2, pp 819-826 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  e g a P | 95
 
 الٌشط هْقعِا لخعييي ًِج -) 41R2SAT( 14 وسخقبلاثل الوز طعن ّحفعيل حصٌيع
 حذيفت رشذي كخاًَإعذاد الطالب: 
  بزّفيسْر رفيق قزهاىالوشزف الزئيسي:  
 
 هلخص:
الاسزشعبس عٓ اٌّىاد اٌّشٌشح ٌّىٓ أْ رىىْ ضبسح فً رجىٌف اٌفُ وٌزحمك ِٓ لجً ِجّىعخ ِٓ ~ 
، اٌزً ٌزُ اٌزعجٍش عٕهب فً اٌخلاٌب اٌحسٍخ اٌّزخصصخ واٌزعشف sR2SATاٌّسزمجلاد، اسّه  23
ضجط  shtdaerbعٍى ِجّىعبد فشدٌخ وٌىٓ رذاخً اٌّشوجبد اٌّشٌشح. اٌّسزمجلاد رخزٍف فً 
واٌزً رزشاوح ِٓ ِسزمجلاد ثصعىثخ إٌى ضجطهب عٍى ٔطبق واسع. واحذ ِٓ ِسزمجلاد اٌطعُ اٌّش 
الاعزشاف ِجّىعخ ِزٕىعخ هبئٍخ ِٓ  41R2SATسع هى الإٔسبْ ضجطهب أوثش عٍى ٔطبق وا
الاصطٕبعٍخ اٌّزٕىعخ وٍٍّبئٍب واٌّشوجبد اٌّشٌشح اٌطجٍعٍخ، ثّب فً رٌه اٌعذٌذ ِٓ اٌعمبلٍش اٌطجٍخ. 
هزا ٌشٍش إٌى أْ هزا اٌّسزمجً ٌّزٍه ٌجٕذ اٌىصىي إٌٍهب ثسهىٌخ جٍت وجٍش ٍِضَ. ٌٍسّبح ٌٍزحمك ِٓ 
) حّض lynehplyhtemid-4،3( -3ٍت ٍِضَ ٌجٕذ. حّض ٍِفٍٕبٍِه (إِىبٍٔخ اٌىصىي وحجُ اٌج
) حّض فًٍٍٕ اٌخً) رُ رحذٌذهب عٍى أٔهب ِحفضاد onilinarolhcid-2،3( -3إٍِٔى) ودٌىٍىفٍٕبن (
جذٌذح فً اَؤخ الأخٍشح فً فحص سٍٍٍىىْ وِٕجهبد وأوذ اٌّمبٌسبد اٌفٍٕخ ورّثً وً  41R2SAT
اٌّضبدح ٌلاٌزهبثبد وِزشبثهخ هٍىٍٍب ٌحّض اٌفٍىفٍٕبٍِه، واٌزً سجك ِٓ اٌّىاد غٍش اٌسزٍشوٌذٌخ 
)، اٌزي ٌّثً enonahteدي (فًٍٍٕ) -3،2-هٍذسووسً-3ٔبهض. اٌجبوي ( 41R2SATرحذٌذهب 
أثسط اٌعطشٌخ وٍزىْ اٌهٍذسووسًٍ وهى عٕصش طجٍعً فً صٌذ اٌٍىص اٌّش، وأٌضب ٌٕزًّ إٌى 
وِب شبثه رٌه رمبسُ وجىد اثٍٕٓ ِٓ فًٍٍٕ ٔظُ حٍمخ ِع حّض  41R2SATِجّىعخ ِٓ ِٕجهبد 
 yxoklaاٌٍّفٍٕبٍِه ودٌىٍىفٍٕبن. ولذ ٌىحظذ الارصبلاد سٍئخ ثٍٓ اٌهٍذسوجٍٓ ِٓ اٌّجّىعبد 
واٌّشزمبد دٌىٍىفٍٕبن لا ٌّىٓ اسزٍعبثهب فً جٍت ٍِضَ ثسجت  53.7262elIٌجٕذ واٌعّىد اٌفمشي 
رجخ اٌٍّفٍٕبٍِه حّض اٌجٕضًٌ اسزش خصبئص ٔبهض، عٍى اٌشغُ ِٓ عبئك اٌفشاغٍخ. الاحزفبظ إٌب
ٍِىشوِزش ٌشٍش إٌى رمًٍٍ فبعٍٍخ، ثبٌٕسجخ ٌىً ِٓ  12عذَ وجىد رٕشٍط ِسزمجلاد ألً رشوٍض ِٓ 
ٍِىشوِزش، فً حٍٓ  12اٌّشزمبد اٌجبوي لاحظٕب سدود ِسزمجلاد لىٌخ ثبٌفعً ثزشوٍضاد رصً إٌى 
 أضعبف أعٍى. 01 ~ 41R2SATبوي ِعذٌخ اٌّطٍىة ٌزفعًٍ وأْ اٌزشوٍض اٌضشوسي ِٓ اٌج
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